Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

Board Website Re-Design Survey
November 15, 2023

MQA is planning to revamp the board websites. Please take the survey to give us your recommendations by clicking the survey icon below. Survey closing Friday, 2/2/2024 at 4:30 PM ET Continue reading


Announcing the FY 2022-23 Annual Report and Long-Range Plan
November 1, 2023

An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading




Survey Button